Life sciences company DiagnoCure Inc.'s (TSX:CUR) fourth-quarter and year-end losses narrowed despite lower revenues.
After the market close Thursday, the Quebec-based company reported a loss of $2.7 million or seven cents a share for the three months ended Oct. 31. That compared with a loss of $3.6 million or nine cents a share in the comparable period a year ago.
Total revenue from sales, research and licence agreements and interest dropped to $351,924 from $502,272.
DiagnoCure lost $12.9 million or 30 cents a share for all of 2009 versus a loss of $13.8 million or 33 cents a share in the prior year.
It booked total revenues of $1.6 million compared with $2 million the previous year. At the end of October, it had cash, short-term and long-term investments totalling $14.6 million.
The company said that the results for the last quarter and full year were in line with management's expectations.
DiagnoCure produces cancer diagnostic tests and delivers laboratory services.
It shares dipped a penny to $1.19 at the close of trading Thursday on the Toronto Stock Exchange.